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Abstract Although significant progress has been made in
the past decade in the treatment of both common and rare
cancers, there has been significant concerns about the cost,
and especially the value, of certain new oncology drugs.
These concerns touch upon a number of issues regarding
the price of these medicines, the value they deliver and the
ability of healthcare systems to fund them. This paper
looks at these perceptions and the extent to which they
apply across different oncology products. Whilst it is
acknowledged there is evidence that the launch price of
pharmaceutical treatments for some forms of cancer has
been rising in recent years, this is not uniformly the case;
we find evidence to the contrary for some forms of cancer.
This is illustrated by the cases of breast and colorectal
cancer. We find cancer medicine prices depend on a
number of factors, including pre-existing treatment options
within a therapeutic class. Indeed, a number of studies have
focused on the cost of treatment per month of overall
survival gained as a simple (although partial) metric to
judge value for money. Given the importance of oncology
products being used in combination, developing similar
approaches to capturing the overall cost of treatment will
be crucial.
Key Points
Looking at cost per month of value gained, evidence
for recent drugs indicates that some new oncology
drugs are delivering additional value and at a lower
cost than pre-existing products.
Given the importance of oncology products being
used in combination, developing new approaches to
capturing the overall cost of treatment will be
crucial.
1 Current Criticisms on New Oncology Products
Although significant progress in the treatment of both
common and rare cancers has been made in the past dec-
ade, there has been significant concern about the cost, and
especially the value, of certain new oncology drugs. These
concerns touch upon a number of issues regarding the price
of these medicines, the value they deliver and the ability of
healthcare systems to fund them [1].
Controversies over the value of and ‘willingness to pay’
for novel therapies have long existed in many high-income
countries with publically funded healthcare systems, such
as Australia, Canada and the UK. This has led to a number
of beliefs and assertions regarding new innovative oncol-
ogy products:
• Launch prices of new anticancer drugs are significantly
and systematically increasing over time, leading to
growing concerns about whether the overall cost of care
is economically ‘unsustainable’ and whether this is
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• Many oncology advances are not delivering significant
benefits to patients or to the healthcare system, leading to
theperception that ‘‘the cost of the newgenerationofdrugs
is getting out of all proportion to the added benefit’’ [4–8].
• Companies are taking advantage of highly inflexible
consumer demand and the pressure on payers to improve
access to cancer treatments to ratchet up prices [2] and are
applying prices based on ‘‘what they can get away with’’
rather than the intrinsic value of the product [6, 8–11].
The high prices of cancer drugs mean the cost of cov-
ering new oncology treatments is becoming unaffordable
for most health systems, which is crowding out other ser-
vices from payer budgets [2, 4, 12, 13]. In this paper, we
look at the evidence underlying these perceptions, how
they apply across different tumour types and whether there
are counter-examples and arguments that might help to
provide a more balanced understanding of the issue.
2 What is Happening to Launch Prices?
Various studies concur that, as a general trend, the launch
price of anticancer drugs has been increasing in recent
years [4, 10]. A 2013 article published in the Journal of
Clinical Oncology found the average monthly price of
cancer drugs in the USA had more than doubled from
$US4500 a decade ago to over $US10,000 [8].
However, there are some examples of recent oncology
products where costs for a month of treatment run counter
to this trend and are delivering additional value at a lower
cost than pre-existing products, reflecting development of
in-class competition and the individual role of additional
treatment options in each therapy area.
Using the Memorial Sloan Kettering Cancer Center
(MSKCC) database (https://www.mskcc.org/research-areas/
programs-centers/health-policy-outcomes/cost-drugs) on can-
cer drug prices, which compiles monthly treatment costs based
on list prices ($US, year 2014 values), we looked at drug prices
for various cancer types (i.e. colorectal, breast cancer). While
some drug prices have increased, a careful look at individual
therapeutic classes demonstrated that the prices of other drugs
are lower than other products in their class.
2.1 Trends in Absolute Prices Versus Total
Treatment Costs
We find that there are exceptions in pricing trends in col-
orectal cancer, where more treatment options have recently
been introduced for patients with metastatic colorectal
cancer (mCRC) along with new ways to combine tradi-
tional agents.
As illustrated in Table 1, both panitumumab (a mono-
clonal antibody targeting tumours that overexpress the
epidermal growth factor receptor) and regorafenib (a
multikinase inhibitor) are delivering additional value at a
cost that is lower than or similar to that of some pre-ex-
isting products. Therefore, prices have not been systemat-
ically trending upward in this particular class of products.
Similarly, considerable advances have been made in the
treatment of certain subtypes of breast cancer. Treatment
options for human epidermal growth factor (HER)-2-posi-
tive metastatic breast cancers include trastuzumab, per-
tuzumab, lapatinib, and trastuzumab–emtansine, and many
more are in development [14]. As shown in Table 2, the
monthly treatment cost of pertuzumab, introduced in 2013,
is significantly lower than the monthly cost of trastuzumab–
emtansine introduced in the same year. In reality, some,
although not all, of the new medicines are primarily used in
combination; hence, the focus should move from the price of
individual medicines to how overall costs are changing.
2.2 Trends in Value for Money
A number of recent studies have demonstrated that cost of
treatment per month of overall survival (OS) gained can be
a useful metric that can be standardised across countries to
easily compare the value for money of treatments [15].
Such analysis may be useful to compare different treat-
ments and help shed light on their relative value.
Table 1 Monthly drug prices for colorectal cancer





($US, year 2014 values)a
Oxaliplatin Eloxatin 2002 5911 7778
Bevacizumab Avastin 2004 4429 5551
Cetuximab Erbitux 2004 9465 11,862
Panitumumab Vectibix 2006 7991 9384
Ziv-aflibercept Zaltrap 2012 11,063 11,407
Regorafenib Stivarga 2012 9620 9919
Bold values indicate additional value at lower or similar cost than existing treatments
a Adjusted for inflation
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Looking at an individual therapeutic class, two studies
by Whalen et al. estimated the incremental cost per month
of median OS (mOS) gained with the use of approved
targeted therapies for colorectal cancer for first, second and
third-line treatment of mCRC in Spain [16] and in France
[17]. Both studies compared the treatment options beva-
cizumab, cetuximab, panitumumab, aflibercept and rego-
rafenib and found the survival gain with targeted therapies
to be higher in first-line than in second- or third-line
treatment. The addition of a targeted agent gave the highest
additional cost per month of OS gain in second-line treat-
ment, followed by first-line treatment; the lowest cost per
month of mOS gain was provided by third-line treatment.
In fact, the latest entrant to the market—regorafenib—had
the lowest cost per month of mOS gain in this analysis
compared with cetuximab (with wild-type KRAS test) in
third-line treatment (Fig. 1). The study showed that, from
2004 to 2015, the incremental cost per mOS gained did not
appear to increase with US FDA approval date.
Although this analysis is simplistic (as it does not
account for all the costs falling on the healthcare system),
the observation that the OS benefit of regorafenib when
coupled with its lower overall cost of treatment per month
of OS gained represents an advance in value relative to
established benchmarks and does challenge the perception
that value for money is worsening progressively.
3 The Role of Medicines in Driving Improvements
in Cancer Survival
Survival has improved significantly in some types of can-
cer. In both Europe and the USA, the 5-year survival rate
has increased steadily over time across many cancer types,
including breast, colorectal and ovarian cancer [18].
However, survival outcomes also vary significantly, and
survival has remained stubbornly low in some cancers such
as lung, pancreas and oesophageal cancers and most brain
tumours [19].
Improvement in health outcomes can be attributed to a
number of factors, including earlier diagnosis, allowing
patients to be treated sooner; however, a recent study
estimated that new medicines have accounted for a sig-
nificant amount of the increase in cancer survival rates
[10].
Advances from new classes and targeted therapies such
as monoclonal antibodies have brought a fundamental
change to our ability to treat cancer and have offered
patients both extra years of life and a higher quality of life
[20]. However, demonstrating the clinical value of a
treatment is an ongoing process involving all aspects of
how the treatment is used in different clinical environments
and how it affects patients and the wider healthcare system.
4 Are New Advances in Oncology Cost Effective?
To assess value, we need to compare both the costs and the
benefits. Given the modest survival benefits (in terms of
days, weeks or months), despite the significant clinical
advantages for patients in terms of additional quality of
life, oncology products often struggle with cost-effective-
ness assessment. It is argued that current methods of cost-
effectiveness analysis do not capture the full value of a
product across all the dimensions that are important from
the patient’s perspective.
A study that looked at growth in the cost of medicines
versus the value of health gains from 1998 to 2005 showed
that although the cost of drug treatment for colorectal
cancer rose, the new treatments also improved patient
Table 2 Monthly drug prices for breast cancer





($US, year 2014 values)a






Ixabepilone Ixempra 2007 6781 7742
Lapatinib ditosylate Tykerb 2007 3124 3567
Everolimus Afinitor 2009 7885 8701
Eribulin mesylate Halaven 2010 6193 6724
Ado-trastuzumab emtansine Kadcyla 2013 10,635 10,807
Pertuzumab Perjeta 2013 7758 7883
Palbociclib Ibrance 2015 10,690 10,677
Bold values indicate additional value at lower or similar cost than existing treatments
Source: Memorial Sloan Kettering Cancer Center database: price and value of cancer drug
a Adjusted for inflation
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health outcomes [21]. In fact, the quality-adjusted cost of
care remained largely flat because of roughly offsetting
gains in health (Fig. 2). More specifically, whilst health-
care costs increased by $US34,493 as a result of the new
medicines, health improved by 0.33115 quality-adjusted
life-years (QALYs), valued at $US33,115 per person.
Thus, the quality-adjusted cost of care increased by only
$US1377 during this time period in the USA [21].
5 Are New Advances in Oncology Unaffordable?
The issue that concerns policy makers is not only the
amount of money currently spent on healthcare but also the
rate of increase in healthcare spending. Therapeutic
oncology spending has increased in most developed
nations, coinciding with the introduction of new biologics
and targeted agents; however, the share of country-level
Fig. 1 Cost per month of median overall survival gained versus
treatment approval date, in France (€). Author’s analysis based on
data from Whalen et al. [17]. FOLFIRI folinic acid, fluorouracil and
irinotecan, FOLFOX4 folinic acid, fluorouracil and oxaliplatin, IFL
irinotecan, fluorouracil, and leucovorin, mOS median overall survival
Fig. 2 Trends in cost of a
24-week colorectal cancer
treatment regimen and change
in quality-adjusted cost of care
for colorectal cancer,
2000–2005. Author’s analysis
based on data by Lakdawalla
et al. [21]
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spending on cancer drugs relative to other drugs has only
increased by about 1% [22].
While the development costs for cancer medicines
account for some of the spending growth, not all increased
costs are attributable to medicines; several other factors also
play a significant role in driving increases in cost [22].
Indeed, if we consider the total costs associated with cancer,
around 60% of total costs derive from productivity losses
and informal care across the EU (Fig. 3), with inpatient
costs accounting for the majority of healthcare costs. One
study of cancer costs in Europe indicated that the main costs
of cancer care accrued in the inpatient setting, representing,
on average, 56% of cancer costs in the EU [23].
New cancer therapies are inevitably one of the main
drivers of the rising cost of cancer care, but they need to be
seen as only part of the cost burden associated with cancer,
along with changes in population demographics such as
aging, improvements in diagnosis and treatment rates, and
increases in the average cost of other aspects of healthcare.
There is also considerable variation in the share of
medicines cost per country, which can be largely explained
by differences in practice (prescribing behaviour, use of
clinical/practice guidelines and readiness to adopt new/in-
novative medicines) as well as differences in reimburse-
ment policies, pricing structures and the affordability ratio
of new oncology medicines across the countries [24].
6 Conclusions
The aim of this paper was to test common assumptions
associated with new oncology medicines. We acknowledge
there is a general upward trend in the cost of pharmaceu-
tical treatments in cancer, but we find tumour types for
which the cost of new anticancer drugs is not increasing
over time. This paper illustrates this with evidence from
breast and colorectal cancer. We suggest that cancer drug
prices depend on a number of factors, including pre-ex-
isting treatment options within a therapeutic class. Indeed,
a number of studies have focused on the cost of treatment
per month of OS gained as a simple (although partial)
metric to judge value for money. Looking at cost per month
of value gained, evidence for recent drugs for mCRC
indicates that some new oncology drugs are delivering
additional value at a lower cost than pre-existing products.
Given the importance of oncology products being used
in combination, the development of similar approaches to
capture the overall cost of treatment will be crucial.
Alongside the development of more sophisticated approa-
ches that can reflect the full value of new innovation,
particularly at the end of a patient’s life where treatments
deliver incremental but vital benefit, metrics, as used in this
paper, provide a useful comparison across products and
between countries. These approaches need to be suffi-
ciently tailored to deal with the different types of oncology
products rather than applying a one-size-fits-all solution.
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